medline.ch Onkologie Urologische Tumoren

	[(68)Ga]Ga-NY104 PET/CT for the detection of clear cell renal cell carcinoma in presurgical patients with renal masses (NYCRPS): a prospective, single-centre, phase II study. Eur J Nucl Med Mol Imaging Yan X, Zheng G, Wang J, Liu M, Chen J, Xie Y, Fu C, Zhang Y, Zhu W, Huo L. PMID: 42020811 [PubMed - as supplied by publisher]
	Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients. Nat Commun Heumann P, Aguado-Barrera ME, Jandu HK, Azria D, Briers E, Bultijnck R, Chang-Claude J, Choudhury A, Dunning AM, Fachal L, Fuentes-Ríos O, Gómez-Caamaño A, Gutiérrez-Enríquez S, Kaaks R, Kerns SL, Lambrecht M, Romero JCR, Rosenstein BS, De Ruysscher D, Schmidt ME, Sperk E, Stobart H, Symonds RP, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML, Rancati T, Rattay T, Vega A, REQUITE Consortium, Talbot CJ, Seibold P. PMID: 42020408 [PubMed - indexed for MEDLINE]
	Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials. Eur Urol Oncol Vauchier C, Thibault C, Velev M, Becker O, Guillaume Z, Ashton E, Zaibet S, Berthou H, Courtinat F, Gervais C, Rochand A, Robbrecht D, Oudard S, Auclin E. PMID: 42020286 [PubMed - as supplied by publisher]
	Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-GuÃ©rin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. Eur Urol Lobo N, Contieri R, Mertens L, Kamat AM. PMID: 42020257 [PubMed - as supplied by publisher]
	Phase 1 Dose-Escalation Study of [(225)Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry. J Nucl Med Ling SW, Konijnenberg M, Segbers M, Hooijman E, Koolen S, de Blois E, De Jong LC, van Puffelen A, de Lussanet de la Sabloniere Q, Bruchertseifer F, Chilug EL, Morgenstern A, van der Veldt A, Brabander T. PMID: 42020144 [PubMed - as supplied by publisher]
	Prostate Cancer Screening in the MR Imaging Era: Evidence, Strategies, and Future Directions. Radiol Clin North Am Cochran RL, Harisinghani MG. PMID: 42020077 [PubMed - indexed for MEDLINE]
	Uncertainty-aware AI for tumor subtyping with histology and immunohistochemistry: A multi-center study in Renal Cell Carcinoma. Comput Methods Programs Biomed Hosseini SMM, Hannetel P, Di Cataldo S, Descombes X, Sibony M, Decaussin M, Ponzio F, Ambrosetti D. PMID: 42019354 [PubMed - as supplied by publisher]
	Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer. Eur J Cancer Develtere D, Tsantoulis P, Olivier T. PMID: 42019224 [PubMed - as supplied by publisher]
	Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study. ESMO Open Cigliola A, Maiorano BA, Rossari F, Tateo V, Mercinelli C, Dizman N, Colecchia M, De Cobelli F, Larcher A, Rosiello G, Briganti A, Montorsi F, Capitanio U, Spiess PE, Agarwal N, Pal SK, Necchi A. PMID: 42019087 [PubMed - as supplied by publisher]
	Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development. Hepatol Res Lim J, Kim SH, Song MJ. PMID: 42018764 [PubMed - as supplied by publisher]
	Diagnostic Approaches to Adult Cystic Nephroma: Insights From Two Cases. Am J Case Rep Bosoteanu M, Vod, Or, Nurla LA, Ciufu N. PMID: 42018497 [PubMed - indexed for MEDLINE]
	TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies. Mol Cancer Ther Hoshi-Kadonosawa Y, Reinhold WC, Taniyama D, Inoue Y, Luna A, Kumar S, Sun NY, Kim YS, Yin JJ, Roper N, Sowalsky AG, Figg WD, Takebe N, Pommier Y. PMID: 42018155 [PubMed - as supplied by publisher]
	CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer. Cancer Immunol Immunother Furriel F, Laranjeira P, Pereira M, Silva S, Silva I, Fontinha G, Sousa V, Gomes C, Parada B, Paiva A. PMID: 42018002 [PubMed - indexed for MEDLINE]
	Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer. Int J Cancer Han Z, Yi X, Tang Y, Li X, Liao D, Xu H, Zheng X, Ai J. PMID: 42017392 [PubMed - as supplied by publisher]
	Uncovering novel germline variants associated with testicular germ cell tumors by exome sequencing. NAR Cancer Cuevas-Estrada B, Ríos-Rodríguez JA, García-Pacheco JA, Wegman-Ostrosky T, Cervera A, Alcaraz N, Montalvo-Casimiro M, Barrón-Hernández A, Castro-Hernández C, Jiménez-Ríos MA, Sobrevilla-Moreno N, Arriaga-Canon C, Herrera LA, González-Barrios R. PMID: 42017013 [PubMed - indexed for MEDLINE]
	PSMA-Targeting Macrophage Membrane-Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer. Exploration (Beijing) Zhang K, Gao B, Wang J, Li Y, Xu C, Yang F, Liu S, Li H, Zhang C, Meng X, Shi Z, Zhang R, Zhang R, Wang Z, Wen W, Zhang Q, Zou Y, Han D, Bian H, Qin W. PMID: 42016765 [PubMed]
	Predicting recurrence of prostate cancer after radical treatment using AI models based on PET/CT radiomics: a dual-center study. Front Oncol Yi Z, Li W, Lou Y, Zhou Q. PMID: 42016705 [PubMed]
	Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study. Int J Urol Ye D, Saad M, Lee JY, Jung W, Pang ST, Li L, Gurney H, Attard G, Chi KN, Mundle S, Zhuo J, Singh A, Lin Y, Sandhu S. PMID: 42015879 [PubMed - indexed for MEDLINE]
	Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial. Int J Cancer Brentnall AR, Rebolj M, Sasieni P, Funston G, Gabe R, Vickers AJ. PMID: 42015666 [PubMed - as supplied by publisher]
	Standardized Program of Resistance Training for Prostate Cancer Patients Receiving Androgen Deprivation Therapy (SPoRT-PCa-ADT): study protocol for a randomized controlled trial. BMC Cancer Soler-López A, Gómez-Carmona CD, González-Devesa D, López-Plaza D, Herrero-Vidal L, Toledo-Pozuelo R, González-Costea A, Cao-Avellaneda E. PMID: 42015017 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 177665

Seite 1 von 8884

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung